Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1

Abstract

We studied the effects of recombinant human growth hormone (r-hGH) on human immunodeficiency virus type 1 replication by growing both wild-type and drug-resistant variants of virus in the presence of various concentrations of eight different antiretroviral drugs. r-hGH had no significant effect on either viral replication or the 50% inhibitory concentrations of these compounds.

FIG. 1.

IC₅₀s of eight ARVs for two wt clinical HIV-1 isolates (a and b) in the presence and absence of r-hGH (logarithmic scale). Each experiment was performed by using three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.

FIG. 2.

IC₅₀s of eight ARVs for five drug-resistant clinical of HIV-1 isolates (a to e) in the presence and the absence of r-hGH (logarithmic scale). The results presented in panels a to e correspond to those for isolates 3 to 7, respectively, in Table 1. Each experiment was performed with three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.

FIG. 2.

IC₅₀s of eight ARVs for five drug-resistant clinical of HIV-1 isolates (a to e) in the presence and the absence of r-hGH (logarithmic scale). The results presented in panels a to e correspond to those for isolates 3 to 7, respectively, in Table 1. Each experiment was performed with three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.

FIG. 2.

IC₅₀s of eight ARVs for five drug-resistant clinical of HIV-1 isolates (a to e) in the presence and the absence of r-hGH (logarithmic scale). The results presented in panels a to e correspond to those for isolates 3 to 7, respectively, in Table 1. Each experiment was performed with three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.

FIG. 2.

IC₅₀s of eight ARVs for five drug-resistant clinical of HIV-1 isolates (a to e) in the presence and the absence of r-hGH (logarithmic scale). The results presented in panels a to e correspond to those for isolates 3 to 7, respectively, in Table 1. Each experiment was performed with three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.

FIG. 2.

IC₅₀s of eight ARVs for five drug-resistant clinical of HIV-1 isolates (a to e) in the presence and the absence of r-hGH (logarithmic scale). The results presented in panels a to e correspond to those for isolates 3 to 7, respectively, in Table 1. Each experiment was performed with three replicate samples and was repeated on at least two different occasions. In no instance were significant differences in IC₅₀s observed between studies performed in the presence or absence of r-hGH. Abbreviations and symbols: ABC, abacavir; TDF, tenofovir; EFV, efavirenz; DLV, delavirdine; NVP, nevirapine; NFV, nelfinavir; APV, amprenavir; LPV, lopinavir; solid bars, control; open bars r-hGH at 10 ng/ml; shaded bars, r-hGH at 20 ng/ml.